- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 13th, 2007
Personalized-medicine startup Nanosphere filed for a $100 million IPO Monday, but an analyst said the move could be a prelude to a merger with one of its larger rivals.
Nanosphere, based in Northbrook, Illinois, makes a system to perform molecular diagnostic tests. Earlier this year Nanosphere applied for U.S. Food and Drug Administration approval of tests to gauge a person's risk of blood clots and how a patient metabolizes the anti-blood clot medicine warfarin, sold under the brand name Coumadin.
The company also is developing tests for cancer, cystic fibrosis gene mutation, herpes viral infection, and cardiovascular disease risk and diagnosis.
|Related News Press|
Nanotech Grants Options September 22nd, 2016
Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Fighting cancer with sticky nanoparticles September 27th, 2016
INVECAS to Enable ASIC Designs for Tomorrow’s Intelligent Systems on GLOBALFOUNDRIES' FDX™ Technology: INVECAS to Collaborate with GLOBALFOUNDRIES to Provide IP and End-to-End ASIC Design Services on 22FDX® and 12FDX™ Technologies September 30th, 2016